The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Microglial activation and dopamine terminal loss in early Parkinson's disease
Abstract
Neuroinflammatory glial response may contribute to degenerative processes in Parkinson's disease (PD). To investigate changes in microglial activity associated with changes in the presynaptic dopamine transporter density in the PD brain in vivo, we studied 10 early‐stage drug‐naive PD patients twice using positron emission tomography with a radiotracer for activated microglia [11 C](R)‐PK11195 and a dopamine transporter marker [11 C]CFT. Quantitative levels of binding potentials (BPs) of [11 C](R)‐PK11195 and [11 C]CFT in the nigrostriatal pathway were estimated by compartment analyses. The levels of [11 C](R)‐PK11195 BP in the midbrain contralateral to the clinically affected side were significantly higher in PD than that in 10 age‐matched healthy subjects. The midbrain [11 C](R)‐PK11195 BP levels significantly correlated inversely with [11 C]CFT BP in the putamen and correlated positively with the motor severity assessed by the Unified Parkinson's Disease Rating Scale in PD. In healthy subjects, the [11 C](R)‐PK11195 BP in the thalamus and midbrain showed an age‐dependent increase. In vivo demonstration of parallel changes in microglial activation and corresponding dopaminergic terminal loss in the affected nigrostriatal pathway in early PD supports that neuroinflammatory responses by intrinsic microglia contribute significantly to the progressive degeneration process of the disease and suggests the importance of early therapeutic intervention with neuroprotective drugs. Ann Neurol 2005;57:168–175
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 2×
“Based on use of the [(11)C](R)PK11195 enantiomer and positron emission tomography (PET), more detailed measurement of microglial activation in vivo recently has been reported in neurodegenerative disorders.(16,17) Furthermore, one of the dopamine transporter (DAT) markers, [(11)C]2- carbomethoxy-3 -(4-fluorophenyl) tr…”
BackgroundMethodMicroglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death
Boje, K. M., & Arora, P. K. (1992) · Brain Research · doi:10.1016/0006-8993(92)91004-x · Cited by 944
Gao, H., Jiang, J., Wilson, B., Zhang, W., Hong, J., & Liu, B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00928.x · Cited by 687
The peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
Cited by
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
“In early stage Parkinson's disease, PET showed an increase of microglial activation, where the level of activation was inversely correlated with density of DA terminals (measured with a dopamine transport marker) and was positively correlated with motor impairmen”
ResultNeuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Role of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
Microglial Activation and Chronic Neurodegeneration
Lull, M. E., & Block, M. L. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.014 · Cited by 1,047
“glia are also present in the SN of living PD patients and are associated with DA neuron damage.(124,125) Thus, evidence”
BackgroundRupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T. C., Fan, J., Akula, N., Groyer, G., Adams, D., & Schumacher, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3295 · Cited by 930
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Microglia-mediated neuroinflammation in neurodegenerative diseases
Subhramanyam, C. S., Wang, C., Hu, Q., & Dheen, S. T. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.004 · Cited by 870
Pisoschi, A. M., Pop, A., Iordache, F., Stanca, L., Predoi, G., & Serban, A. I. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112891 · Cited by 816
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Alternatively activated microglia and macrophages in the central nervous system
Franco, R., & Fernández-Suárez, D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.003 · Cited by 650
Qin, X.-Y., Zhang, S.-P., Cao, C., Loh, Y. P., & Cheng, Y. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2742 · Cited by 554
Microglial Activation in Young Adults With Autism Spectrum Disorder
Suzuki, K., Sugihara, G., Ouchi, Y., Nakamura, K., Futatsubashi, M., Takebayashi, K., Yoshihara, Y., Omata, K., Matsumoto, K., Tsuchiya, K. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.272 · Cited by 523
Self-citationTranslocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair
Chen, M.-K., & Guilarte, T. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.12.004 · Cited by 506
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
Glia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 424
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
“2012, 271732 51 Ouchi, Y. et al. (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease.”
BackgroundMethamphetamine causes microglial activation in the brains of human abusers
Sekine, Y., Ouchi, Y., Sugihara, G., Takei, N., Yoshikawa, E., Nakamura, K., Iwata, Y., Tsuchiya, K. J., Suda, S., Suzuki, K., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1179-08.2008 · Cited by 381
Self-citationVenneti, S., Lopresti, B. J., & Wiley, C. A. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.10.002 · Cited by 373
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Theodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 367
A possible role for humoral immunity in the pathogenesis of Parkinson's disease
Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H., & Halliday, G. M. (2005) · Brain · doi:10.1093/brain/awh625 · Cited by 350
Microglia Function in Alzheimer’s Disease
Solito, E., & Sastre, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00014 · Cited by 349
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324
“CD45RO+ expression also positively correlates with UPDRS motor score.”
BackgroundAnti-inflammatory drugs and risk of Parkinson disease: A meta-analysis
Gagne, J. J., & Power, M. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d5a4a3 · Cited by 322
Chronic stress and glucocorticoids: From neuronal plasticity to neurodegeneration
Vyas, S., Rodrigues, A. J., Silva, J. M., Tronche, F., Almeida, O. F. X., Sousa, N., & Sotiropoulos, I. (2016) · Neural Plasticity · doi:10.1155/2016/6391686 · Cited by 297
Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons
Mount, M. P., Lira, A., Grimes, D., Smith, P. D., Faucher, S., Slack, R., Anisman, H., Hayley, S., & Park, D. S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5321-06.2007 · Cited by 315
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“In PD, chronic activation of microglia can trigger polarization toward the cytotoxic M1 macrophages, leading to a self–perpetuating persistent inflammatory environment (294, 295), considered to be amajor factor in driving dopaminergic degeneration (267, 296, 297).”
BackgroundDopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE‐PD)
Williams‐Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P., Evans, J. R., Cummins, G. A., Duncan, G. W., Khoo, T. K., Burn, D. J., et al. (2016) · Movement Disorders · doi:10.1002/mds.26563 · Cited by 304
Daniele, S. G., Béraud, D., Davenport, C., Cheng, K., Yin, H., & Maguire-Zeiss, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.2005965 · Cited by 303
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Chen, X., Hu, Y., Cao, Z., Liu, Q., & Cheng, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02122 · Cited by 288
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
Oxidative Stress in Parkinson's Disease: A Systematic Review and Meta-Analysis
Wei, Z., Li, X., Li, X., Liu, Q., & Cheng, Y. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00236 · Cited by 281
Werry, E. L., Bright, F. M., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kril, J. J., & Kassiou, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133161 · Cited by 279
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“…activation and corresponding DAergic terminal loss in the affected nigrostriatal pathway in early PD supports that neuroinflammatory responses by intrinsic microglia contribute to the progressive degeneration in PD and related diseases (Kim and Joh 2006; Ouchi et al. 2005; Wilms et al. 2007).”
BackgroundPeriphery and brain, innate and adaptive immunity in Parkinson’s disease
Harms, A. S., Ferreira, S. A., & Romero-Ramos, M. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02268-5 · Cited by 272
Physical Exercise Inhibits Inflammation and Microglial Activation
Mee-inta, O., Zhao, Z.-W., & Kuo, Y.-M. (2019) · Cells · doi:10.3390/cells8070691 · Cited by 268
Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases
Spielman, L. J., Gibson, D. L., & Klegeris, A. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.005 · Cited by 266
Biomarker of Neuroinflammation in Parkinson’s Disease
Liu, T.-W., Chen, C.-M., & Chang, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084148 · Cited by 259
Kölliker-Frers, R., Udovin, L., Otero-Losada, M., Kobiec, T., Herrera, M. I., Palacios, J., Razzitte, G., & Capani, F. (2021) · Mediators of Inflammation · doi:10.1155/2021/9999146 · Cited by 258
“In 2005, another study suggested microglia-mediated in fl ammation presenting at an early stage of par-kinsonism [33].”
Sanchez-Guajardo, V., Febbraro, F., Kirik, D., & Romero-Ramos, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008784 · Cited by 256
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration
Purisai, M. G., McCormack, A. L., Cumine, S., Li, J., Isla, M. Z., & Di Monte, D. A. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.008 · Cited by 254
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Ros-Bernal, F., Hunot, S., Herrero, M. T., Parnadeau, S., Corvol, J.-C., Lu, L., Alvarez-Fischer, D., Carrillo-de Sauvage, M. A., Saurini, F., Coussieu, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017820108 · Cited by 231
Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Gelsomino, G., Moresco, R. M., & Perani, D. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.07.002 · Cited by 221
“The problems with [ 11 C]-PK11195 PET analysis are highlighted by the seeming disparity between the results reported by previous studies [14] [16], and by the report of Bartels and coworkers [15] , in which different analysis methods resulted in totally different results.”
BackgroundResultInfluentialTSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control
Gatliff, J., East, D., Crosby, J., Abeti, R., Harvey, R., Craigen, W., Parker, P., & Campanella, M. (2014) · Autophagy · doi:10.4161/15548627.2014.991665 · Cited by 215
Parkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum
Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05697.x · Cited by 189
“Caffeine attenuated MPTP-induced gliosis in striatum Activation of astrocytes and microgila occurs in PD patients (Forno et al. 1992; Ouchi et al. 2005; Gerhard et al. 2006) and in animal models of PD including MPTP (Francis et al. 1995; Kohutnicka et al. 1998; Liberatore et al. 1999).”
BackgroundDupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
“…10 HC 11C-PK11195 Midbrain tracer BPND in PD group greater than in the healthy volunteers No significant difference in thalamus or striatum binding Ouchi et al. (2005) [49] - 18 PD patients with a wide range of disease severity vs. 11 HC - 8 PD patients with a longitudinal follow-up (PET after…”
BackgroundInflammation in Parkinson’s disease: role of glucocorticoids
Herrero, M.-T., Estrada, C., Maatouk, L., & Vyas, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00032 · Cited by 175
Yokokura, M., Mori, N., Yagi, S., Yoshikawa, E., Kikuchi, M., Yoshihara, Y., Wakuda, T., Sugihara, G., Takebayashi, K., Suda, S., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1612-0 · Cited by 174
Self-citationIncreased Immune Activation by Pathologic α‐Synuclein in Parkinson's Disease
Grozdanov, V., Bousset, L., Hoffmeister, M., Bliederhaeuser, C., Meier, C., Madiona, K., Pieri, L., Kiechle, M., McLean, P. J., Kassubek, J., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25557 · Cited by 161
Zhang, Q.-S., Heng, Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.002 · Cited by 156
Zhang, S., Wang, X.-J., Tian, L.-P., Pan, J., Lu, G.-Q., Zhang, Y.-J., Ding, J.-Q., & Chen, S.-D. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-154 · Cited by 154
“Activated microglia are found in the SN of mesencephalon in the brain of PD patients [5-8] and of parkinsonian animal models [9-13].”
BackgroundEarly microglial activation and peripheral inflammation in dementia with Lewy bodies
Surendranathan, A., Su, L., Mak, E., Passamonti, L., Hong, Y. T., Arnold, R., Vázquez Rodríguez, P., Bevan-Jones, W. R., Brain, S. A. E., Fryer, T. D., et al. (2018) · Brain · doi:10.1093/brain/awy265 · Cited by 154
“Inflammation has also been seen early in Parkinson’s disease in the brainstem, and cortical inflammation is seen before the onset of dementia (Ouchi et al., 2005; Gerhard et al., 2006; Edison et al., 2013).”
BackgroundDrouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu103 · Cited by 153
“For commercial re-use, please contact journals.permissions@oup.com Background: Accumulating evidence supports a role for the immune system in the pathogenesis of Parkinson’s disease.”
BackgroundMcGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A., Lee, D., Chang, J., Dubow, J., Dhall, R., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00378-2 · Cited by 153
Barcia, C., Ros, C. M., Annese, V., Carrillo-de Sauvage, M. A., Ros-Bernal, F., Gómez, A., Yuste, J. E., Campuzano, C. M., de Pablos, V., Fernandez-Villalba, E., et al. (2012) · Scientific Reports · doi:10.1038/srep00809 · Cited by 150
Toll-like receptors and their therapeutic potential in Parkinson’s disease and α-synucleinopathies
Kouli, A., Horne, C. B., & Williams-Gray, C. H. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.042 · Cited by 143
Striatal Neuroinflammation Promotes Parkinsonism in Rats
Choi, D.-Y., Liu, M., Hunter, R. L., Cass, W. A., Pandya, J. D., Sullivan, P. G., Shin, E.-J., Kim, H.-C., Gash, D. M., & Bing, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005482 · Cited by 141
Microglial activation in healthy aging
Schuitemaker, A., van der Doef, T. F., Boellaard, R., van der Flier, W. M., Yaqub, M., Windhorst, A. D., Barkhof, F., Jonker, C., Kloet, R. W., Lammertsma, A. A., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.016 · Cited by 142
A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis
Nutma, E., Stephenson, J. A., Gorter, R. P., de Bruin, J., Boucherie, D. M., Donat, C. K., Breur, M., van der Valk, P., Matthews, P. M., Owen, D. R., et al. (2019) · Brain · doi:10.1093/brain/awz287 · Cited by 138
Positron Emission Tomography Imaging of Neuroinflammation
Cagnin, A., Kassiou, M., Meikle, S. R., & Banati, R. B. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.04.006 · Cited by 137
Mesocorticolimbic Dopamine Pathways Across Adolescence: Diversity in Development
Reynolds, L. M., & Flores, C. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.735625 · Cited by 137
Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease
Schröder, J. B., Pawlowski, M., Meyer zu Hörste, G., Gross, C. C., Wiendl, H., Meuth, S. G., Ruck, T., & Warnecke, T. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01081 · Cited by 134
The Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease
Baizabal-Carvallo, J. F., & Alonso-Juarez, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.02.030 · Cited by 130
Lavisse, S., Goutal, S., Wimberley, C., Tonietto, M., Bottlaender, M., Gervais, P., Kuhnast, B., Peyronneau, M.-A., Barret, O., Lagarde, J., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.11.011 · Cited by 127
Imaging of microglia in patients with neurodegenerative disorders
Politis, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00096 · Cited by 111
Microglial activation in Parkinson’s disease using [18F]-FEPPA
Ghadery, C., Koshimori, Y., Coakeley, S., Harris, M., Rusjan, P., Kim, J., Houle, S., & Strafella, A. P. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0778-1 · Cited by 113
“Thus far, several studies have explored the relationship between neuroinflammation and PD by using the first and most widely used radioligand [(11)C]-PK11195 [10, 11].”
Tentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., Moestrup, S. K., & Romero-Ramos, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-16.2016 · Cited by 109
Pannell, M., Economopoulos, V., Wilson, T. C., Kersemans, V., Isenegger, P. G., Larkin, J. R., Smart, S., Gilchrist, S., Gouverneur, V., & Sibson, N. R. (2020) · Glia · doi:10.1002/glia.23716 · Cited by 109
“The use of specific radiopharmaceuticals targeting TSPO in combination with positron emission tomography (PET) imaging has allowed activated glia to be observed in patients with Parkinson's disease (Ouchi et al., 2005), multiple sclerosis, glioma (Tarkkonen, Rissanen, Tuokkola, & Airas, 2016), amyloid lateral sclerosi…”
BackgroundImaging Striatal Microglial Activation in Patients with Parkinson’s Disease
Koshimori, Y., Ko, J.-H., Mizrahi, R., Rusjan, P., Mabrouk, R., Jacobs, M. F., Christopher, L., Hamani, C., Lang, A. E., Wilson, A. A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138721 · Cited by 100
López González, I., Garcia-Esparcia, P., Llorens, F., & Ferrer, I. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020206 · Cited by 101
The Role of Anti-Inflammatory Agents in Parkinson???s Disease
McGeer, E. G., & McGeer, P. L. (2007) · CNS Drugs · doi:10.2165/00023210-200721100-00001 · Cited by 95
Differential distribution and activation of microglia in the brain of male C57BL/6J mice
Yang, T.-T., Lin, C., Hsu, C.-T., Wang, T.-F., Ke, F.-Y., & Kuo, Y.-M. (2013) · Brain Structure and Function · doi:10.1007/s00429-012-0446-x · Cited by 92
Mirzaei, N., Tang, S. P., Ashworth, S., Coello, C., Plisson, C., Passchier, J., Selvaraj, V., Tyacke, R. J., Nutt, D. J., & Sastre, M. (2016) · Glia · doi:10.1002/glia.22978 · Cited by 82
Yao, R., Pan, R., Shang, C., Li, X., Cheng, J., Xu, J., & Li, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00986 · Cited by 79
“The phagocytosis of microglia requires dynamic cytoskeletal reorganization, which requires a large amount of energy (Pan et al., 2019).”
BackgroundRoser, A.-E., Tönges, L., & Lingor, P. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00094 · Cited by 77
Cerami, C., Iaccarino, L., & Perani, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050993 · Cited by 75
Borrajo, A., Rodriguez-Perez, A. I., Villar-Cheda, B., Guerra, M. J., & Labandeira-Garcia, J. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.021 · Cited by 75
Suridjan, I., Rusjan, P. M., Voineskos, A. N., Selvanathan, T., Setiawan, E., Strafella, A. P., Wilson, A. A., Meyer, J. H., Houle, S., & Mizrahi, R. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.09.021 · Cited by 71
Liu, S.-Y., Qiao, H.-W., Song, T.-B., Liu, X.-L., Yao, Y.-X., Zhao, C.-S., Barret, O., Xu, S.-L., Cai, Y.-N., Tamagnan, G. D., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02574-z · Cited by 62
“Studies also evaluated the associations between microglia activation and dopaminergic denervation measured by either tracers of dopaminergic transporter or Fdopa, which reported inconsistent results [12, 15, 18, 21].”
BackgroundBehavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal
Kang, S. S., Kurti, A., Baker, K. E., Liu, C.-C., Colonna, M., Ulrich, J. D., Holtzman, D. M., Bu, G., & Fryer, J. D. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx366 · Cited by 62
Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson’s Disease
Labandeira-Garcia, J. L., Rodríguez-Perez, A. I., Villar-Cheda, B., Borrajo, A., Dominguez-Meijide, A., & Guerra, M. J. (2015) · The Neuroscientist · doi:10.1177/1073858414554954 · Cited by 54
Scheffold, A., Holtman, I. R., Dieni, S., Brouwer, N., Katz, S.-F., Jebaraj, B. M. C., Kahle, P. J., Hengerer, B., Lechel, A., Stilgenbauer, S., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0364-x · Cited by 53
“cussed being detrimental elements in PD [69, 70].”
Liu, Z., Chen, H.-Q., Huang, Y., Qiu, Y.-H., & Peng, Y.-P. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.08.006 · Cited by 51
He, Q., Li, Y., Guo, S., Wang, Y., Lin, W., Zhang, Q., Wang, J., Ma, C., & Xiao, B. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13132 · Cited by 48
RetractedErnest James Phillips, T., & Maguire, E. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.652593 · Cited by 33
“well as work by McGeer and colleagues on post-mortem tissue, demonstrate increased microglial activation in PD brains (McGeer et al., 1988; Ouchi et al., 2005; Gerhard et al., 2006).”
BackgroundParkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
Bortolanza, M., do Nascimento, G. C., Raisman‐Vozari, R., & Del‐Bel, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15439 · Cited by 33
Vicente-Rodríguez, M., Singh, N., Turkheimer, F., Peris-Yague, A., Randall, K., Veronese, M., Simmons, C., Karim Haji-Dheere, A., Bordoloi, J., Sander, K., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.05.025 · Cited by 28
Wang, D., Gao, H., Qin, Q., Li, J., Zhao, J., Qu, Y., Li, J., Xiong, Y., Min, Z., Mao, Z., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04881-w · Cited by 25
Drobny, A., Ngo, P. A., Neurath, M. F., Zunke, F., & López-Posadas, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655123 · Cited by 24
Metadata
- Authors
- Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2005-01-24
- Volume
- 57
- Issue
- 2
- Pages
- 168-175
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2021356347
- Cited by
- 843
- References
- 39
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.